SCHEDULE 13G/A: Tang Capital Group Discloses 8.4% Stake in CytomX Therapeutics
Beneficial Ownership Report
Tang Capital Management, LLC and affiliated entities, including Kevin Tang, have filed an amended Schedule 13G, disclosing a beneficial ownership of 8.4% in CytomX Therapeutics, Inc. as of March 31, 2025.
Summary
- Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP collectively reported beneficial ownership of 6,717,825 shares of CytomX Therapeutics, Inc. common stock.
- This represents 8.4% of the company's outstanding common stock, based on 80,099,889 shares outstanding as of February 28, 2025, as reported in the Issuer's Annual Report on Form 10-K filed on March 6, 2025.
- The reporting persons, as a group, share both voting and dispositive power over these 6,717,825 shares.
- The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in tone. However, the presence of a significant institutional investor can be perceived as a slight positive by the market.
Positives
- A significant beneficial ownership stake of 8.4% by Tang Capital, a notable investment firm, may signal confidence in CytomX Therapeutics' future prospects.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a routine disclosure of beneficial ownership and does not provide specific analysis of broader industry trends or competitors.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership. The presence of a notable investment firm as a major shareholder could potentially influence investor confidence and market perception.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date as of which 80,099,889 shares of Common Stock were outstanding, as per Issuer's Form 10-K. |
| 03/06/2025 | Date Issuer's Annual Report on Form 10-K was filed with the Securities and Exchange Commission. |
| 03/31/2025 | Date of event which requires filing of this statement. |
| 05/15/2025 | Date the Schedule 13G was signed and filed. |
Keywords
CytomX Therapeutics, CTMX, Tang Capital Management, Kevin Tang, Schedule 13G, beneficial ownership, common stock, institutional ownership, biotechnology, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.